Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant for prevention of CINV in pediatric solid tumors receiving MEC/HEC multi-day chemotherapy
ChiCTR2000035363Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pediatric solid tumors comparing Fosaprepitant arm with Placebo arm (2 arms). Primary endpoint: Complete response rate for vomiting in overall phase. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
fosaprepitant
03
Conditions
pediatric solid tumors
Beyond the preview
Go deeper on ChiCTR2000035363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035363.